This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial)

September 9th, 2014

This study of 1358 children investigated whether intermittent montelukast (a drug widely used to treat wheeze and other asthmatic symptoms) compared with placebo, reduced wheezing episodes in children aged 10 months to 5 years, and whether patient outcome differed according to genotype.

Study authors found that intermittent montelukast only reduced wheezing episodes in children with arachidonate 5-lipoxygenase (ALOX5) gene promoter 5/5, a gene that has previously been associated with a better response to montelukast in adults. There was no correlation with reduced wheezing episodes for children without this specific genotype.

Therefore the researchers call for more research into the effects of montelukast in children with this genetic subtype.

More information:
www.thelancet.com/journals/lan … (14)70186-9/abstract

Provided by Lancet

Citation: Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial) (2014, September 9) retrieved 23 July 2026 from https://sciencex.com/wire-news/171685015/intermittent-montelukast-in-children-aged-10-months-to-5-years-w.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.